Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 136

1.

Indices related to apo CII and CIII serum concentrations and coronary heart disease: a case-control study.

Gerber Y, Goldbourt U, Segev S, Harats D.

Prev Med. 2003 Jul;37(1):18-22.

PMID:
12799125
2.

Association between serum apolipoprotein C(II) concentration and coronary heart disease.

Gerber Y, Goldbourt U, Cohen H, Harats D.

Prev Med. 2002 Jul;35(1):42-7.

PMID:
12079439
3.

Presence of Apo B48, and relative Apo CII deficiency and Apo CIII enrichment in uremic very-low density lipoproteins.

Atger V, Beyne P, Frommherz K, Roullet JB, Drüeke T.

Ann Biol Clin (Paris). 1989;47(8):497-501. Review.

PMID:
2690681
4.

Modulation of lipoprotein B binding to the LDL receptor by exogenous lipids and apolipoproteins CI, CII, CIII, and E.

Clavey V, Lestavel-Delattre S, Copin C, Bard JM, Fruchart JC.

Arterioscler Thromb Vasc Biol. 1995 Jul;15(7):963-71.

5.

Determination of apolipoprotein B in apolipoprotein CII/CIII-containing lipoproteins by an immunoenzymmetric assay.

Sandkamp M, Tambyrajah BM, Assmann G, Schriewer H.

Eur J Clin Chem Clin Biochem. 1992 Apr;30(4):223-8.

PMID:
1525253
6.

Decreased VLDL apoprotein CII/apoprotein CIII ratio may be seen in both normotriglyceridemic and hypertriglyceridemic patients on chronic hemodialysis treatment.

Wakabayashi Y, Okubo M, Shimada H, Sato N, Koide A, Marumo F, Nakamura H.

Metabolism. 1987 Sep;36(9):815-20.

PMID:
3626863
8.

LDL containing apolipoprotein CIII is an independent risk factor for coronary events in diabetic patients.

Lee SJ, Campos H, Moye LA, Sacks FM.

Arterioscler Thromb Vasc Biol. 2003 May 1;23(5):853-8. Epub 2003 Mar 13.

9.

VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial.

Sacks FM, Alaupovic P, Moye LA, Cole TG, Sussex B, Stampfer MJ, Pfeffer MA, Braunwald E.

Circulation. 2000 Oct 17;102(16):1886-92.

10.

Alterations of lipids and apolipoprotein CIII in very low density lipoprotein subspecies in type 2 diabetes.

Hiukka A, Fruchart-Najib J, Leinonen E, Hilden H, Fruchart JC, Taskinen MR.

Diabetologia. 2005 Jun;48(6):1207-15. Epub 2005 Apr 30.

PMID:
15864534
11.

Distribution of CII and CIII peptides in lipoprotein classes: methods and clinical significance.

Graziani MS, Zanolla L, Righetti G, Marchetti C, Zanotto G, Lupo A.

Clin Chem. 1994 Feb;40(2):240-4.

12.

Immunoturbidimetric techniques for quantifying apolipoproteins CII and CIII.

Rifai N, Silverman LM.

Clin Chem. 1986 Oct;32(10):1969-72.

13.

[The ratios of apoC-III/apoC-II in normal full-term maternal bloods and their umbilical cord bloods].

Ikeda H, Ikeda T.

Rinsho Byori. 2001 Jan;49(1):45-50. Japanese.

PMID:
11215483
14.

Apolipoprotein profile in type II diabetic patients with and without coronary heart disease.

Barbagallo CM, Averna MR, Amato S, Marino G, Labisi M, Rao AC, Barbagallo M, Cupidi GF, Notarbartolo A.

Acta Diabetol Lat. 1990 Oct-Dec;27(4):371-7.

PMID:
2087939
15.

Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men.

Pischon T, Girman CJ, Sacks FM, Rifai N, Stampfer MJ, Rimm EB.

Circulation. 2005 Nov 29;112(22):3375-83.

16.

[The significance of the distribution of apolipoprotein C-III in serum lipoproteins].

Ikeda H.

Rinsho Byori. 2003 Jul;51(7):609-14. Japanese.

PMID:
12924243
19.

[Serum lipids and apolipoproteins AI, B100, CI, CII, and CIII in 142 patients with coronary heart disease].

Liu BW, Shao MZ, Yuan HJ, Wu ZF, Zhang ZH, Fu MD, Zhang RJ, Fan P.

Hua Xi Yi Ke Da Xue Xue Bao. 1989 Jun;20(2):119-22. Chinese.

PMID:
2512245
20.

Supplemental Content

Support Center